Maynard Um
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $21 at Jefferies
-
-
-
-
-
-
-
Morgan Stanley Upgrades 4D Molecular Therapeutics (FDMT) to Equalweight
-
-
-
-
-
-
-
4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q1 EPS
-
-
-
-
-
-
-
Morgan Stanley Starts 4D Molecular Therapeutics (FDMT) at Underweight
-
-
-
-
-
-
-
4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 5c
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
443,944 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

